Axogen, Inc. filings document a Nasdaq-listed operating company focused on peripheral nerve repair technologies and related surgical products. Form 8-K reports furnish quarterly and annual operating results, Regulation FD investor presentations, FDA-related disclosures for Avance® (acellular nerve allograft-arwx), and material agreements tied to common stock financing and shelf registration activity.
Proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and pay-versus-performance disclosures. The filing record also identifies Axogen’s common stock structure and corporate governance framework, while event reports record officer compensation arrangements, regulatory language for Avance, and other formal updates to the company’s public disclosure record.
AXGN filing: Notice of proposed sale under Rule 144. The form lists 3,878 shares of Common stock with a transaction date shown as 05/07/2026 and Nasdaq as the market. The filing identifies two blocks of restricted stock: 541 shares (03/16/2023) and 3,337 shares (02/01/2024), and names Morgan Stanley Smith Barney LLC Executive Financial Services as the broker.
Axogen, Inc. ownership update: First Light Asset Management, LLC and Mathew P. Arens jointly report beneficial ownership stakes in Axogen common stock via a Schedule 13G/A (Amendment No. 3).
First Light reports 3,291,463 shares (6.19%) and Mr. Arens reports 3,617,993 shares (6.80%), including 187,000 shares held solely by Mr. Arens. The filing is a joint statement per Item 2 and includes a Joint Filing Agreement.
Vanguard Capital Management reports beneficial ownership of 2,659,776 shares of Axogen Inc common stock, representing 5.12% of the class.
The Schedule 13G states Vanguard has sole voting power for 368,213 shares and sole dispositive power for 2,659,776 shares. The filing attributes holdings to Vanguard funds and managed accounts. The form is signed 04/29/2026.
Axogen, Inc. will hold its 2026 Annual Meeting of Shareholders as a virtual-only audio webcast on June 23, 2026 at 8:30 a.m. Eastern time. Holders of 53,177,824 common shares outstanding as of April 24, 2026 may vote on electing eight directors, ratifying Deloitte & Touche LLP as independent auditor, and approving a non-binding advisory vote on executive pay. The proxy highlights 2025 performance, including 20.2% revenue growth and improved EBITDA, as well as FDA approval of the biologics license application for Avance as an acellular nerve scaffold. It also details board independence, committee structure, ownership levels, equity plans and pay-for-performance incentive design for named executive officers.
Axogen, Inc. reported strong top-line growth but a larger net loss for the quarter ended March 31, 2026. Revenue rose to $61,457, up 26.6% from the prior year period, driven mainly by higher unit volumes and pricing.
Gross profit increased to $46,189 and gross margin improved to 75.2%, helped by lower inventory write-offs and shipping costs. Operating expenses grew to $49,021 as the company expanded sales, marketing and R&D, resulting in a loss from operations of $2,832.
Net loss widened to $19,584, largely due to a $16,849 loss on extinguishment of debt after Axogen used $69,707 of proceeds from a $133,252 equity offering to repay and terminate its Credit Facility. Cash, cash equivalents and investments increased to $101,601, and management believes this liquidity and product sales will fund operations for at least the next twelve months.
Axogen, Inc. reported strong first quarter 2026 results and raised its full-year 2026 revenue guidance to at least 20% growth, or $270 million. Q1 2026 revenue was $61.5 million, up 26.6% from $48.6 million a year earlier, with gross margin improving to 75.2% from 71.9%.
The company recorded a GAAP net loss of $19.6 million (–$0.38 per share), largely driven by a $16.8 million loss on extinguishment of debt. On a non‑GAAP basis, Axogen reported adjusted net income of $4.1 million ($0.07 per diluted share) and adjusted EBITDA of $5.7 million, a 9.3% margin.
Cash, restricted cash, and investments rose to $103.6 million as of March 31, 2026, from $45.5 million at year‑end 2025, aided by an upsized public offering of 4.6 million shares that generated $133.3 million in net proceeds. The company used $69.7 million of these proceeds to fully repay and terminate its Oberland loan facility. Management expects 2026 gross margin between 74% and 76% and to be free cash flow positive for the full year.